Fat Loss & Metabolism

Survodutide

BI 456906 · dual GLP-1/glucagon agonist

experimentalcutting-edgesubQ injection

What it is

Survodutide is Boehringer Ingelheim and Zealand Pharma's dual GLP-1/glucagon agonist, advanced through Phase 2 with strong weight-loss numbers. Showed ~19% body weight reduction at the highest dose in 46-week trials — competitive with Tirzepatide and approaching Retatrutide.

How it works

Same dual-receptor mechanism as Cotadutide: GLP-1 for appetite, glucagon for energy expenditure and liver fat clearance. Survodutide has demonstrated particularly strong effects on MASH (liver disease) markers.

Benefits

Up to ~19% body weight loss at highest doses (Phase 2 data)
Strong MASH/NAFLD improvements
Improved cardiovascular markers
Glycemic benefits in type 2 diabetes patients

Timeline

Week 1–4: Appetite suppression; titration nausea common.
Week 24: 10–15% body weight loss.
Week 46: Peak ~19% (highest dose, Phase 2).

Dosing & titration

Trial dose2.4–6 mg subQ once weekly

TitrationSlow weekly upward titration

When to titrate upInvestigational; not commercially available.

Side effects & risks

Standard GLP-1 side effects (nausea, vomiting, GI)
Possible glycemic shifts
Long-term safety still being established

Phase 3 trials ongoing. Likely FDA approval timeline 2026–2027 if data holds.

Typical price

N/A — investigationalNot commercially available outside trials.

Studies

le Roux CW et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity — Phase 2 NEJM paper. NEJMNEJM, 2024
Search PubMed for survodutide — PubMed searchLive PubMed search

Educational reference only. Not medical advice.